Updated:
Shifamed
Amr Salahieh's Shifamed builds medical device companies from scratch, spinning out over a dozen startups including Shockwave Medical since 2009.
Shifamed
Shifamed is a medical technology incubator that develops new medical products from concept to commercial release. It has made 32 investments, including a Series D investment in Supira Medical on November 21, 2023.
General information
Firm type
Asset Manager
Year founded
2009
AUM
Undisclosed
Location
Region
Europe
Country
United States
City
Campbell
Corporate office
Campbell, CA, United States
Principals
Amr Salahieh
Founder & CEO
Sector focus
Frequently asked questions
How does Shifamed source its investment opportunities?
Shifamed does not source external deals. The firm generates its own pipeline internally: the founding team identifies clinical problems, develops the initial technology and intellectual property, and then forms a new company to commercialize it. This makes deal flow fully proprietary and independent of traditional venture-origination channels (public record).
Is Shifamed a venture capital fund?
No. Shifamed is a privately funded incubator and holding entity. It does not raise committed capital from limited partners, does not charge management fees, and does not operate on a fund cycle. Each portfolio company is a legally independent entity in which Shifamed and co-investors hold equity (per the firm's official communications).
Who runs investment decisions at Shifamed?
Founder and CEO Amr Salahieh controls all strategic and investment decisions. He personally determines which technologies advance to company formation and which co-investors participate in each spinout (per the firm's official communications).
Does Shifamed participate in fund commitments or only direct deals?
Shifamed only makes direct, equity-holding investments in companies it creates internally. It does not commit capital to third-party venture funds, nor does it act as a limited partner in external vehicles (public record).
What happened to Shockwave Medical and why is that significant?
Shockwave Medical, a Shifamed-founded company that developed intravascular lithotripsy for calcified arterial disease, was acquired by Johnson & Johnson for $13.1 billion in a deal that closed in 2024 (per Bloomberg, 2023). The exit validated Shifamed's concentrated incubation model and returned substantial capital to its founding stakeholders.
How is Shifamed structured in relation to its portfolio companies?
Each portfolio company is a legally distinct entity with its own management team, board, and capitalization structure. Shifamed holds an equity stake in each but does not operate them as subsidiaries. This allows companies to raise independent financing and pursue their own exit paths (per the firm's official communications).
What is Shifamed's known posture on co-investments alongside external parties?
Shifamed selectively brings in co-investors on a per-company basis, typically large institutional healthcare funds and strategic corporate partners. These co-investors participate in funding rounds for individual spinouts rather than in Shifamed itself, which remains entirely privately held by its founder (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: